BR0306855A - Método para o tratamento de distúrbios cognitivos - Google Patents

Método para o tratamento de distúrbios cognitivos

Info

Publication number
BR0306855A
BR0306855A BR0306855-2A BR0306855A BR0306855A BR 0306855 A BR0306855 A BR 0306855A BR 0306855 A BR0306855 A BR 0306855A BR 0306855 A BR0306855 A BR 0306855A
Authority
BR
Brazil
Prior art keywords
cognitive disorders
treatment
carbamoylseroline
alzheimer
phenyl
Prior art date
Application number
BR0306855-2A
Other languages
English (en)
Inventor
Nigel Greig
Gosse Bruinsma
Original Assignee
Axonyx Inc
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axonyx Inc, Us Gov Health & Human Serv filed Critical Axonyx Inc
Publication of BR0306855A publication Critical patent/BR0306855A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

"MéTODO PARA O TRATAMENTO DE DISTúRBIOS COGNITIVOS". A presente invenção refere-se a composições e métodos para o tratamento de doenças que resultam de distúrbios cognitivos, tal como doença de Alzheimer com o composto (-)N-(-)-N fenil carbamoileserolina como o ingrediente ativo.
BR0306855-2A 2002-03-22 2003-03-18 Método para o tratamento de distúrbios cognitivos BR0306855A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36706802P 2002-03-22 2002-03-22
US10/386,915 US20040024043A1 (en) 2002-03-22 2003-03-12 Method for treating cognitive disorders
PCT/US2003/008407 WO2003082270A1 (en) 2002-03-22 2003-03-18 Method for treating cognitive disorders

Publications (1)

Publication Number Publication Date
BR0306855A true BR0306855A (pt) 2005-04-05

Family

ID=28678179

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0306855-2A BR0306855A (pt) 2002-03-22 2003-03-18 Método para o tratamento de distúrbios cognitivos

Country Status (16)

Country Link
US (1) US20040024043A1 (pt)
EP (1) EP1490057A4 (pt)
JP (1) JP2005526806A (pt)
KR (1) KR100609381B1 (pt)
CN (1) CN1642541A (pt)
AU (1) AU2003230683B2 (pt)
BR (1) BR0306855A (pt)
CA (1) CA2476923A1 (pt)
HR (1) HRP20040992A2 (pt)
IL (1) IL163993A0 (pt)
MX (1) MXPA04009136A (pt)
NO (1) NO20044530L (pt)
NZ (1) NZ534726A (pt)
PL (1) PL372315A1 (pt)
RU (1) RU2280449C2 (pt)
WO (1) WO2003082270A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2309594T3 (es) * 2003-11-21 2008-12-16 Memory Pharmaceuticals Corporation Composiciones que contienen bloqueadores de los canales de calcio de tipo l e inhibidores de la colinesterasa.
EP1737445A4 (en) 2004-03-19 2007-05-09 Axonyx Inc METHOD FOR TREATING DOWN SYNDROME
US20070213388A1 (en) * 2004-03-19 2007-09-13 Bruinsma Gosse B Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Antagonists Useful in the Treatment of of Cognitive Disorders
US9095573B2 (en) * 2005-08-01 2015-08-04 University Of Central Florida Research Foundation, Inc. Method of biasing implanted human neural stem cells away from differentiation into glial cells by (+)phenserine to modulate the concentration of soluble βAPP in tissue or CSF
RU2327480C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом
US9006283B2 (en) 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
US8962677B2 (en) 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
US20120225922A1 (en) 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
CA2994974C (en) 2015-08-14 2024-04-09 Qr Pharma Methods of treatment or prevention of acute brain or nerve injuries
US10111860B1 (en) 2016-01-15 2018-10-30 Aristea Translational Medicine Corporation Compositions and methods for treating concussion
US10864192B2 (en) 2016-01-15 2020-12-15 Aristea Translational Medicine Corporation Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions
WO2017214197A1 (en) 2016-06-06 2017-12-14 University Of Central Florida Research Foundation, Inc. Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions
US20180338950A1 (en) 2017-05-24 2018-11-29 Qr Pharma, Inc. Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis Via Administration of Posiphen to Healthy or Sick Humans
US12582632B2 (en) 2021-05-18 2026-03-24 Annovis Bio, Inc. Inhibition of neurological injuries due to infections via administration of Butanetap and analogs thereof
KR20260026542A (ko) * 2023-06-21 2026-02-26 아노비스 바이오, 인크. 포시펜 d-타르트레이트의 고체 형태
WO2025017530A1 (en) * 2023-07-19 2025-01-23 Assia Chemical Industries Ltd. Solid state forms of buntanetap and process for preparation thereof
WO2025255358A1 (en) * 2024-06-06 2025-12-11 Annovis Bio, Inc. Solid forms of posiphen d-tartrate and processes of preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409948A (en) * 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
RU2123858C1 (ru) * 1994-09-13 1998-12-27 Белокоскова Светлана Георгиевна Способ лечения афазии
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
EP1349858B1 (en) * 2000-11-02 2008-08-27 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof

Also Published As

Publication number Publication date
CN1642541A (zh) 2005-07-20
US20040024043A1 (en) 2004-02-05
JP2005526806A (ja) 2005-09-08
RU2004131214A (ru) 2005-04-10
IL163993A0 (en) 2005-12-18
EP1490057A1 (en) 2004-12-29
EP1490057A4 (en) 2007-07-11
PL372315A1 (en) 2005-07-11
AU2003230683B2 (en) 2006-04-06
CA2476923A1 (en) 2003-10-09
NZ534726A (en) 2006-06-30
AU2003230683A1 (en) 2003-10-13
RU2280449C2 (ru) 2006-07-27
NO20044530L (no) 2004-10-21
WO2003082270A1 (en) 2003-10-09
KR20040101319A (ko) 2004-12-02
KR100609381B1 (ko) 2006-08-08
MXPA04009136A (es) 2004-12-07
HRP20040992A2 (en) 2005-02-28

Similar Documents

Publication Publication Date Title
UY28011A1 (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
ES2282685T3 (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
BR0312729A (pt) Novos derivados de indol-3-enxofre
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BR0214035A (pt) Composto
UY28817A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegerativos
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
DE502004006619D1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
GB0223038D0 (en) Therapeutic compounds
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
ECSP056192A (es) 3-fluoro-piperidinas como antagonistas de nmda/nr2b
ATE446285T1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
ATE489948T1 (de) Behandlung von autoimmunkrankheiten
PA8608601A1 (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
DE502004006525D1 (de) Verwendung von feigenkaktus (opuntia) zur herstellung eines medikaments zur behandlung von depressionen
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
DE60217292D1 (de) Veterinärmedizinische dermatologische zusammensetzung
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/407; A61P 25/28

Ipc: A61K 31/403 (2011.01), A61P 25/28 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES.